

Improving the lives of women with breast cancer

August 2022

#### **Forward-Looking Statements**

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans, the scope, progress, results and costs of developing our product candidate or any other future product candidates, expected manufacturing capabilities, strategy, regulatory matters, including the timing and likelihood of success of obtaining drug approvals, market size and opportunity and our ability to complete certain milestones. Words such as "believe," "anticipate," "plan," "expect," "intend," "will," "may," "goal," "project," "estimate," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks inherent in developing products and technologies, future results from the Company's ongoing and planned clinical trials, the Company's ability to obtain adequate financing to fund its planned clinical trials and other expenses, trends in the industry, the legal and regulatory framework for the industry and future expenditures, and other risks and uncertainties affecting Olema, including those described under the caption "Risk Factors" and elsewhere in Olema's quarterly report on Form 10-Q filed on August 9, 2022 and future filings and reports of Olema with the Securities and Exchange Commission. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given.

This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.



## **Olema Oncology Overview**

#### **Developing Next-Generation Therapies in Women's Oncology**



Lead candidate: **OP-1250** - a <u>Complete Estrogen Receptor An</u>tagonist (CERAN) in development for the treatment of ER+/HER2- metastatic breast cancer



Phase 2 clinical development ongoing with attractive emerging profile Preparing for initiation of pivotal Phase 3 monotherapy trial in mid-2023



Internally-discovered, wholly-owned IP with no royalty burden Received Fast Track designation from U.S. FDA in July 2022



Research pipeline of additional women's cancer programs complementary to OP-1250




Strong balance sheet with \$240.7M\* cash position; Sufficient capital to fund clinical and development operations into 2H 2024

Nasdaq OLMA





## **OP-1250: Best-in-Class Potential for ER+ / HER2- Breast Cancer**



## **OP-1250 Clinical Status as of July 2022**

#### **Rapidly Advancing Clinical Development of OP-1250 to Pivotal Studies**

High investigator enthusiasm and robust enrollment continues across program; Granted FDA Fast Track Designation

#### Phase 1b Monotherapy Expansion



- As of July 1, 2022, 50 patients have been treated in Phase 1b (N=25 each for 60 and 120 mg dose cohorts)
- Favorable tolerability; most adverse events (AEs) were Grade 1 or 2, with most common treatment-related AEs were nausea, vomiting, fatigue and headache
- Encouraging anti-tumor activity in initial set of expansion patients evaluated
  - 4 partial responses in 31 efficacy-evaluable patients\*
- Phase 2 enrollment ongoing at Recommended Phase 2 Dose of 120 mg OP-1250 once-daily

#### Phase 1b Combination with Palbociclib

- Dose escalation progressing
  - 30, 60 and 90 mg cohorts have completed DLT evaluation period; 120 mg cohort ongoing
- Combinability demonstrated in initial completed cohorts:
  - $\checkmark$  No dose limiting toxicities
  - ✓ Tolerability profile consistent with that of palbociclib plus endocrine therapy
  - $\checkmark$  No induced metabolism of palbociclib

Upcoming Milestones Q3 2022: Initiate Phase 1b combo study with ribociclib and alpelisib

Q4 2022: Present monotherapy and initial combination data

Mid-2023: Initiate pivotal monotherapy study




 $\bigcirc$ 

Data and anticipated milestones stated above are as of July 1, 2022; \*1 confirmed partial response at 60 mg and 3 unconfirmed partial responses, pending confirmation at a subsequent scan, at 120 mg

#### **EMERALD Study Validates Opportunity in 2L+ Setting for OP-1250**

- Hazard ratio of 0.55 in *ESR1<sub>mut</sub>* patients is clinically meaningful and validates the opportunity to beat SoC in the 2L+ setting
- ESR1 mutations are the most common resistance mechanism to SoC in the 1<sup>st</sup> line setting leading to progression in up to 50% of patients
- ESR1 mutations typically occur within the ligand binding domain resulting in a constitutively active ER in the absence of estrogen ligand binding
- Elecestrant, a SERM/SERD, acts as a partial antagonist on • *ESR1<sub>mut</sub>* receptors but can have partial agonist activity on WT receptors
- OP-1250 has the potential to improve upon the EMERALD . result given its activity on both mutant ESR1 and wild-type receptors



#### Patients With Tumors Harboring *mESR1*


OP-1250, a Complete Estrogen Receptor Antagonist (CERAN), completely turns off both AF1 and AF2 transcriptional domains in <u>both</u> mutant ESR1 and wild-type receptors




#### MAINTAIN Study Validates Opportunity in Both 1L and 2L+ Settings for OP-1250

Fulvestrant's pharmacology limited by:

- Poor bioavailability
- Reduced potency in *ESR1<sub>mut</sub>* receptors compared to WT due to mutation in ligand binding domain



- Fulvestrant's efficacy benefit limited to wild-type ESR1 receptors; suboptimal drug exposure results in an inability to shut-off mutant ESR1 receptor
- MAINTAIN results consistent with PARSIFAL; unable to shut-off the most common resistance mechanism to 1<sup>st</sup> line treatment



OP-1250 has potential to improve upon fulvestrant due to favorable pharmacokinetics, ~10-fold higher exposure levels enables stronger binding affinity in *ESR1<sub>mut</sub>* receptors



References: Andreano K et al. Molecular Cancer Therapeutics. May 7, 2020. Kalinsky et al. Proceedings: MAINTAIN trial presentation. ASCO Annual Meeting; June 3-7, 2022.

OP-1250: Designed to Shut Down ER-Driven Cell Growth and Proliferation in ER+/HER2- Breast Cancer



1

## **ER+ Breast Cancer — A Significant Unmet Need**

#### Breast Cancer is the Most Common Diagnosed Cancer Worldwide




New endocrine agents needed to suppress or overcome resistance, and delay toxic chemotherapy



## **Segments of Therapy in ER+/HER2- Breast Cancer**






<sup>1</sup>2025 incidence projection estimates. Olema internal data, Informa ER+ HER2- BC Prevalence Based Market Forecast. 26% of adjuvant eligible patients assumed to have Ki-67 ≥ 20%. Early breast cancer incidence includes high risk adjuvant segment. <sup>2</sup>2025 incidence projection estimates. Olema internal data, Informa HER2+ BC Prevalence Based Market Forecast. Forecast based on 3L+ HR+ HER2+ metastatic breast cancer projections. <sup>3</sup>Olema internal data. <sup>4</sup>2025 opportunity estimates for total endocrine therapy market (US and EU5). Olema internal data.

10

## **Understanding the Estrogen Receptor (ER)**

The Estrogen Receptor is a Tripartite Protein with Two Distinct Transcriptional Activation Domains (AF1 and AF2)



Estrogen receptor, unbound, remains in the-ptosition.


When Estrogen binds the ER, both AF1 and AF2 can drive transcription and cancer cell proliferation.



## **OP-1250** is a Complete Estrogen Receptor Antagonist (CERAN)


SERM / SERDs Only Block AF2 Activity but Allow AF1 Activation

Tamoxifen, a partial antagonist, turns off AF2 but not AF1



Partial antagonists have a short duration of response for treatment of metastatic breast cancer **CERANs Completely Block Both AF1 and AF2 Activity** 

Complete antagonists turn off AF2 and recruit N-CoR to inactivate AF1



#### CERANs block AF1 activity, even in the presence of signaling, preventing cell proliferation


References: Shang and Brown, Science, 29 Mar 2002: Vol. 295, Issue 5564, pp. 2465-2468 Webb, Nguyen, and Kushner, JBC, Vol. 278, 28 Feb 2003, pp. 6912–6920



12

#### **OP-1250 Non-Clinical Data Summary**

#### **OP-1250 Non-Clinical Data Consistent with Emerging Clinical Profile**






## **OP-1250: Interim Phase 1 Clinical Data**



## **OP-1250 Study 001: First-in-Human Phase 1/2 Clinical Study Design**

#### OP-1250 oral, once-daily dosing



#### Phase 1 Key Inclusion Criteria:

- ER+/HER2- advanced breast cancer
- ≥1 prior endocrine therapy for advanced breast cancer
- ≤2 prior chemotherapy regimens for locally advanced or metastatic disease


#### **OP-1250** Phase 1a Study Population Received Extensive Prior Therapy

Patient Characteristics	N=41 (%*)
Median age (years)	63
ECOG performance status	
0	17 (41)
1	24 (59)
Measurable disease at baseline	31 (76)
Visceral disease (liver, lung, peritoneum, pleura, ascites)	25 (61)
Prior lines of therapy in advanced settings	Median=3 (Range 1-8)
Prior lines of endocrine therapy in advanced settings <sup>+</sup>	Median=2
1	12 (29)
2	13 (32)
3 or more	15 (37)
Types of prior therapies in advanced settings	
Chemotherapy	17 (42)
Aromatase inhibitor (AI)	31 (76)
Fulvestrant	28 (68)
CDK 4/6 inhibitor	39 (95) <sup>‡</sup>
ESR1 mutations at baseline (ctDNA), n=39 evaluated	19 (49) <sup>§</sup>

\*Sums may not total to 100% due to rounding <sup>†</sup>One patient had missing data <sup>‡</sup>Nine patients received 2 prior CDK4/6i regimens <sup>§</sup>ctDNA was not collected in 2 patients. ECOG, Eastern Cooperative Oncology Group; CDK4/6, cyclin-dependent kinases



#### **Dose-Proportional PK with Attractive Steady-State Plasma Concentrations**



- High oral bioavailability and steady-state plasma levels with minimal peak-to-trough variability
- Doses ≥60 mg QD exceed predicted efficacy thresholds

- Enables complete antagonism of the estrogen receptor without the need for higher daily doses
- Effective half life (T<sub>1/2</sub>)=51-73 hours, supporting once-daily dosing



#### **Favorable Tolerability Profile**

TRAEs in ≥15%	30 mg (n=5)		60 mg (n=6)		90 mg (n=6)		120 mg (n=6)		150 mg (n=4)		210 mg (n=7)		300 mg (n=7)		Total N=41 (%)	
of Patients	All	G≥3	All	G≥3	All	G≥3	All	G≥3	All	G≥3	All	G≥3	All	G≥3	All	G≥3
Patients with ≥1 event	4	1	3	0	2	0	5	0	2	1	6	1	6	1	28 (68)	4 (10)
Nausea	1	0	2	0	1	0	5	0	1	0	4	0	6	1	20 (49)	1 (2)
Fatigue	2	0	3	0	0	0	1	0	1	1	3	0	4	0	14 (34)	1 (2)
Vomiting	0	0	1	0	1	0	2	0	0	0	1	0	4	0	9 (22)	0
Headache	0	0	1	0	0	0	1	0	1	0	0	0	4	0	7 (17)	0


- Adverse events primarily grade 1 or 2 across all dose levels
- No dose limiting toxicities and maximum tolerated dose not reached
- No clinically significant bradycardia, ocular toxicity or diarrhea

Targeted RP2D range of 60 to 120 mg based on pharmacokinetics, favorable tolerability, and initial efficacy



#### **OP-1250 Demonstrated Meaningful Anti-Tumor Activity**


#### Best Response of Target Lesion in Patients with Measurable Disease (N=22)



\*Patient's response unconfirmed due to progression with a new non-target lesion at follow-up visit. Efficacy-evaluable patients include those with measurable disease at baseline and at least one post-baseline scan. Data cut-off: November 1, 2021. CDK4/6i, cyclin-dependent kinases inhibitor; AI, aromatase inhibitor.



#### **Durable Clinical Benefit Observed in Heavily Pretreated Population**



\*Four patients in the 300 mg cohort dose reduced, 3 to 120 mg and 1 to 60 mg with most occurring at the beginning of cycle 2. These patients were included in RP2D CBR calculation. CBR defined as SD persisting ≥24 weeks, or a best response of confirmed CR or PR. ORR includes patients with measurable disease only. AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinases inhibitor. Data cut-off: November 1, 2021.



### **OP-1250: Successful Phase 1a with Key Objectives Achieved**



Highly Attractive Pharmacokinetics

- High oral bioavailability
- Dose proportional PK with exposures supporting once-daily dosing
  - Smooth profile with minimal peak-to-trough variability
- Effective half-life of 51-73 hours
- Doses ≥60 mg QD exceed predicted efficacy thresholds
  - Enables complete antagonism of ER without the need for higher daily doses



- Generally well tolerated
- Adverse events (AEs) were mostly Grade 1 or 2 at all dose levels
- No DLTs observed and MTD not reached
- No clinically significant bradycardia, ocular toxicity, or diarrhea. Low rates of neutropenia seen and identified as an AE of special interest
- RP2D range of 60 to 120 mg identified based on favorable PK, tolerability, and initial efficacy



**Promising Anti-Tumor Efficacy** 


- Clear efficacy signals observed in heavily pretreated patients
- 3 partial responses observed in patients with ESR1 mutations\*
  - 2 confirmed and 1 unconfirmed
  - Durable cPRs ≥8months
- RP2D range (60-120 mg):
   ORR: 17% (2/12), CBR: 46% (6/13)
- Robust target lesion reductions ≥30% observed in 4 response-eligible patients
- 13 of 41 (32%) patients remain on study as of data cut-off date

#### Potential best-in-class backbone endocrine therapy of choice for ER+ breast cancer



## Phase 1b Combination Study with Palbociclib: Study Design

#### Initiated January 2022




#### **Key Inclusion Criteria:**

- ER+/HER2- advanced breast cancer
- Evaluable disease (measurable and non-measurable)
- ≤ 1 prior hormonal regimen for locally advanced or metastatic disease
- Can be CDK4/6i naïve or pre-treated



## Phase 1b Combination Study with Ribociclib and Alpelisib: Study Design

Initiating in Q3 2022



RP2D of OP-1250 for combination with either ribociclib or alpesilib Secondary objectives: ORR (CR + PR), CBR (CR + PR + SD  $\geq$  24 weeks) RP2D in combination with either ribociclib or alpesilib



#### **Rapidly Advancing OP-1250 Clinical Development Toward Pivotal Phase 3 Studies**

1H 2022	<ul> <li>✓ Select RP2D</li> <li>✓ Initiate Phase 2 cohorts         <ul> <li>Measurable disease (N=50)</li> <li>Non-measurable disease (N=15)</li> <li>CNS metastasis (N=15)</li> </ul> </li> <li>✓ Initiated Phase 1b combination study with palbociclib</li> </ul>
2H 2022	<ul> <li>Initiate Phase 1b study of OP-1250 in combination with each of ribociclib and alpelisib</li> <li>Present updated monotherapy and initial combination data in Q4 2022</li> </ul>
2023	<ul> <li>Present additional monotherapy and combination data</li> <li>Initiate pivotal 2L+ monotherapy study mid-2023</li> </ul>

Building evidence to support OP-1250's potential as a differentiated, best-in-class CERAN



## **Olema Oncology Pipeline**

		Discovery	Nonclinical	Phase I	Phase II	Phase III	Clinical Collaboration		
	Metastatic Breast Cancer								
l	ER+, HER2- MBC (with and without CNS metastases)								
	ER+, HER2- MBC (combination with palbociclib)						<b>P</b> fizer		
	ER+, HER2- MBC (combination with ribociclib)						ပံ novartis		
	ER+, HER2- MBC with PIK3CA mutated (combination with alpelisib)						U NOVARTIS		
OP-1250	ER+ with ESR1 mutation <sup>(1)</sup>								
	HER2+ Metastatic Breast Cancer with CNS METS								
	ER+, HER2+ MBC with CNS metastases								
	Gynecology – Oncology								
	Endometrial Cancer <sup>(1)</sup>								
	Gynecologic malignancies								
	Discovery Pipeline								
	Breast Cancer target								
	Undisclosed Oncology target								

MBC = metastatic breast cancer; PI3K $\alpha$  = phosphatidylinositol 3-kinase alpha; CDK4/6i = CDK4/6 inhibitor (1) Patient population may be studied as additional cohort(s) of current Phase 1/2 clinical trial or may be studied in a separate clinical trial.





Investor Relations ir@olema.com Media media@olema.com Business Development partnering@olema.com


Careers careers@olema.com

## Appendix





#### **Both CERANs and SERM/SERDs are Strong Degraders of ER**α




- OP-1250 and CERANs strongly degraded the estrogen receptor (ER) in five ER+ cell lines
- Partial and strong agonists demonstrated variable and inconsistent ER degradation
- Estradiol (E2), the prototypical agonist of ERα, degraded ERα in all five ER+ cell lines

In all cases, none of the compounds achieved full ER degradation; <u>Complete ER antagonism</u> is independent from degradation and key to inactivating remaining ER receptor






#### CERANs Inactivate Both AF1 & AF2 Activity While SERM/SERDs Only Inactivate AF2





CERANs completely inactivate AF1 activity of the estrogen receptor, while partial and strong agonists (SERM/SERDs) do not fully inhibit AF-1 activity

#### **OP-1250** Has Demonstrated Robust Tumor Shrinkage in Both ESR1 Wild-Type and Mutant Xenograft Models



References:








Hodges-Gallagher et al., Abstract P5-05-02, Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas Hodges-Gallagher et al., Abstract 4376, Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA

#### **OP-1250 Demonstrated Robust Activity in an Intracranial Breast Cancer Brain Metastases Xenograft Study**

10 mg/kg OP-1250 is superior to tamoxifen, fulvestrant and ovariectomy in shrinking mutant ESR1-Y537S tumors in an intracranial model of ER+ breast cancer brain metastasis



Treatment	Endpoint	n
Vehicle PO, QD	PD SD PR CR	0 0 0
Vehicle + OVX PO, QD	PD SD PR CR	7 1 0 0
5 mg Fulvestrant sc, qw	PD SD PR CR	8 0 0 0
60 mg/kg Tamoxifen PO, QD	PD SD PR CR	6 1 1 0
10 mg/kg OP-1250 PO, QD	PD SD PR CR	0 0 4 4
10 mg/kg OP-1250 + 75 mg/kg Ribociclib PO, QD	PD SD PR CR	0 0 1 7


Endpoint criteria: PD (progressed disease) >20% increase tumor size; PR (partial response) >30% decrease in tumor size; CR (complete response): no tumor observed; SD (stable disease): does not meet above criteria.

After 100 days, tumors in mice treated with OP-1250 remain small or undetectable while tumors in mice treated with fulvestrant and tamoxifen have started to grow.



Reference: Hodges-Gallagher et al., Proceedings: AACR Annual Meeting 2021; April 9-14, 2021

## AACR 2021: Intracranial Breast Cancer Brain Metastases Xenograft Study




#### **OP-1250 vs. Fulvestrant and Tamoxifen: Prolonged Survival Impact**

 Dosing stopped in OP-1250 10 mg/kg group at 100 days

 OP-1250 prevented death in all animals at day 120. Data suggest that OP-1250 may be an active treatment for patients with brain metastasis from ER+ breast cancer.

OP-1250 was superior in shrinking ER+ tumors compared to other endocrine therapies tested, including fulvestrant and tamoxifen.

# SABCS 2021: Addition of OP-1250 to Anti-HER2 Agents Improved Inhibition of Tumor Growth in Nonclinical Models of ER+/HER2+ Breast Cancer



- Approximately 25% of breast cancer tumors are HER2+, about half of which are also ER+
- HER2+ tumors have a high rate of brain metastasis
- HER2CLIMB regimen (tucatinib + trastuzumab + capecitabine) has shown efficacy for treatment of HER2+ brain metastases
- OP-1250 in combination with HER2 inhibitors, trastuzumab and tucatinib, inhibited
   ER+/HER2+ xenograft growth at least as well as capecitabine



## Thank you

